Compound comparison
A structured research comparison between Cortagen and Thymulin across compound identity, research category, evidence maturity, and interpretation boundaries.
Short peptide bioregulator
Proposed as a tissue-associated short peptide bioregulator; target-level evidence remains limited.
Preclinical foundation
The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.
Thymic immune-signaling peptide
Studied as a thymic signaling peptide with immune and endocrine context; identity is distinct from thymosin alpha 1.
Early human evidence
The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.
| Dimension | Cortagen | Thymulin |
|---|---|---|
| Catalog identity | Cortagen is mapped to short peptide bioregulator research. | Thymulin is mapped to thymic immune-signaling peptide research. |
| Research category | Cortagen is primarily organized around neural bioregulator models. | Thymulin is primarily organized around immune and endocrine signaling. |
| Interpretive boundary | Use the Cortagen profile and verified study pages before inferring mechanism or outcomes. | Use the Thymulin profile and verified study pages before inferring mechanism or outcomes. |
Comparison pages organize differences; they do not establish superiority, equivalence, or individual suitability.
Short peptide bioregulator literature index
PubMed, U.S. National Library of Medicine · Database
Atlas internal research database
Internal Research Database · 2026 · Database
Thymulin literature index
PubMed, U.S. National Library of Medicine · Database
Continue the research map
